# US 2008/0187548 A1 · Ny-Eso-1 Peptides Which Bind To Class II Molecules And Uses Thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0187548 A1 - Document ID: US20080187548A1 - Status: Published application - Kind: A1 - Application number: 10/547,896 - Filed: 2004-03-01 - Published: 2008-08-07 - Earliest claimed: 2003-03-04 - Assignees: Ludwig Institute for Cancer Research - Inventors: Michael Pfreudschuh; Frank Neumann; Hans-George Rammensee; Stefan Stevanovic - Web page: https://patentgrep.com/patent/US20080187548A1 ## CPC - C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE} - A61K 39/001188: {NY-ESO} - A61P 35/00: Antineoplastic agents - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55}) - A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to peptides which consist of amino acid sequences found in the NY-ESO-1 molecule, which bind to MHC-Class II molecules. These can be used alone, or in combination with other peptides. ## Claims ### Claim 1 An isolated peptide consisting of the amino acid sequence set forth in SEQ ID NO: 2. ### Claim 2 (depends on 1) A composition useful in stimulating a CD4+ response, comprising the isolated peptide of claim 1, and an adjuvant. ### Claim 3 (depends on 1) A composition useful in stimulating a T cell response in a subject, comprising the isolated peptide of claim 1, and at least one additional peptide. ### Claim 4 (depends on 3) The composition of claim 3, wherein said at least one additional peptide consists of an amino acid sequence found in NY-ESO-1. ### Claim 5 (depends on 3) The composition of claim 3, wherein said at least one additional peptide binds to an MHC Class I molecule and stimulates a CD8+ T cell response. ### Claim 6 (depends on 3) The composition of claim 3, wherein said at least one additional peptide binds to an MHC Class II molecule and stimulates CD4+ T cell response. ### Claim 7 (depends on 3) The composition of claim 3, further comprising a pharmaceutically acceptable carrier. ### Claim 8 (depends on 7) The composition of claim 7, wherein said pharmaceutically acceptable carrier is an adjuvant. ### Claim 9 An isolated nucleic acid molecule consisting of a nucleotide sequence which encodes a peptide, the amino acid sequence of which is set forth in SEQ ID NO: 2. ### Claim 10 (depends on 9) Expression vector comprising the isolated nucleic acid molecule of claim 9, operably linked to promoter. ### Claim 11 (depends on 9) Recombinant cell comprising the isolated nucleic acid molecule of claim 9. ### Claim 12 (depends on 10) Recombinant cell comprising the expression vector of claim 10. ### Claim 13 (depends on 1) An isolated CD4+ T cell which recognizes a complex of the isolated peptide of claim 1 and an MHC Class II molecule. ### Claim 14 (depends on 13) A composition comprising the isolated CD4+ T cell of claim 13, and a pharmaceutically acceptable carrier. ### Claim 15 (depends on 1) A method for provoking T cell response in a subject comprising administering an amount of the isolated peptide of claim 1 to said subject in an amount sufficient to stimulate a T cell response. ### Claim 16 (depends on 15) The method of claim 15, wherein said T cell response is a CD4+ T cell response. ### Claim 17 (depends on 15) The method of claim 15, wherein said subject suffers from cancer. ### Claim 18 (depends on 17) The method of claim 17, wherein said cancer cells of said subject express NY-ESO-1 molecules. ### Claim 19 (depends on 1) A soluble T cell receptor which is specific for a complex of an HLA molecule and the isolated peptide of claim 1. ### Claim 20 (depends on 1) An isolated antibody or binding fragment of an antibody which specifically binds to a complex of an HLA molecule and the isolated peptide of claim 1. ### Claim 21 (depends on 20) The isolated antibody of claim 20, wherein said antibody is a monoclonal antibody. ### Claim 22 (depends on 21) A hybridoma cell line which produces the monoclonal antibody of claim 21.